Catalyst Pharmaceuticals Inc (CPRX)
15.15
-0.24
(-1.53%)
USD |
NASDAQ |
Jun 25, 16:00
15.16
+0.01
(+0.07%)
After-Hours: 20:00
Catalyst Pharmaceuticals Research and Development Expense (TTM): 92.17M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 92.17M |
| December 31, 2023 | 93.15M |
| September 30, 2023 | 95.27M |
| June 30, 2023 | 19.92M |
| March 31, 2023 | 19.95M |
| December 31, 2022 | 19.79M |
| September 30, 2022 | 20.69M |
| June 30, 2022 | 16.86M |
| March 31, 2022 | 17.33M |
| December 31, 2021 | 16.94M |
| September 30, 2021 | 16.12M |
| June 30, 2021 | 15.38M |
| March 31, 2021 | 15.28M |
| December 31, 2020 | 16.50M |
| September 30, 2020 | 18.63M |
| June 30, 2020 | 19.48M |
| March 31, 2020 | 19.76M |
| December 31, 2019 | 18.84M |
| September 30, 2019 | 20.95M |
| June 30, 2019 | 20.89M |
| March 31, 2019 | 19.97M |
| December 31, 2018 | 19.92M |
| September 30, 2018 | 14.91M |
| June 30, 2018 | 13.07M |
| March 31, 2018 | 11.82M |
| Date | Value |
|---|---|
| December 31, 2017 | 11.38M |
| September 30, 2017 | 10.79M |
| June 30, 2017 | 10.58M |
| March 31, 2017 | 10.64M |
| December 31, 2016 | 11.37M |
| September 30, 2016 | 12.38M |
| June 30, 2016 | 12.93M |
| March 31, 2016 | 13.00M |
| December 31, 2015 | 11.80M |
| September 30, 2015 | 10.35M |
| June 30, 2015 | 10.20M |
| March 31, 2015 | 9.719M |
| December 31, 2014 | 10.12M |
| September 30, 2014 | 9.802M |
| June 30, 2014 | 9.720M |
| March 31, 2014 | 9.753M |
| December 31, 2013 | 8.097M |
| September 30, 2013 | 6.773M |
| June 30, 2013 | 4.624M |
| March 31, 2013 | 3.025M |
| December 31, 2012 | 2.660M |
| September 30, 2012 | 2.875M |
| June 30, 2012 | 2.834M |
| March 31, 2012 | 3.207M |
| December 31, 2011 | 3.384M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.28M
Minimum
Mar 2021
95.27M
Maximum
Sep 2023
29.70M
Average
19.62M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.67B |
| Sarepta Therapeutics Inc | 832.10M |
| PTC Therapeutics Inc | 587.57M |
| Corcept Therapeutics Inc | 202.01M |
| Vertex Pharmaceuticals Inc | 3.209B |